The impact of cost-sharing schemes on drug compliance in Italy: Evidence based on quantile regression

International Journal of Public Health

Volumn 59, Issue 2, 2014, Pages 329-339

  Atella, Vincenzo ^a   Kopinska, Joanna Aleksandra ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cholesterol; Co payments; Compliance; Cost sharing; Difference in differences; Quantile regression; Statins

Indexed keywords

COST; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; ITALY; LONGITUDINAL STUDY; MALE; MEDICATION COMPLIANCE; REGRESSION ANALYSIS;

COST SHARING; DATABASES, FACTUAL; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; ITALY; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; REGRESSION ANALYSIS;

EID: 84899442312     PISSN: 16618556     EISSN: 1420911X     Source Type: Journal    
DOI: 10.1007/s00038-013-0528-4     Document Type: Article

References (26)

1. Atella V, Kopinska J (2012) Criterio di ripartizione e simulazione a medio e lungo termine della spesa sanitaria in italia: una proposta operativa Mimeo
2. Atella V, Schafheutle E, Noyce P (2005) Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Policy 4(1):23-35 (Pubitemid 41352123)
3. Atella V, Peracchi F, Depalo D, Rossetti C (2006a) Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients. Health Econ 15:875-892 (Pubitemid 44463365)
4. Atella V, Rosati FC, Rossi MC (2006) Precautionary saving and health risk. Evidence from the Italian households using a time series of cross sections. Rivista di Politica Economica 96(3):113-132
5. Avogaro A, Guida P, Giorda C, Mannucci E, Medea G, Comaschi M, Velussi M, Armienti G, Zucchetti R (2007) The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Metab Cardiovasc 17(1):32-40 (Pubitemid 44889279)
6. Borah B (2011) Assessing predictors of medication adherence in unconditional quantile regression framework. Value Health 14(3):A8
7. Borah B, Burns M, Shah N (2011) Assessing the impact of high deductible health plans on health-care utilization and cost: A changes-in-changes approach. Health Econ 20:1025-1042
8. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS (2005) Determinants of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165:1147-1152 (Pubitemid 40720739)
9. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH (2008) Costeffectiveness of providing full drug coverage to increase medication adherence in post myocardial infarction medicare beneficiaries. Am Heart Assoc Circ 117:1261-1268 (Pubitemid 351365674)
10. Deambrosis P, Seramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, Chinellato A (2007) Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 63:197-203 (Pubitemid 46147062)
11. Ellis JJ, Erickson RS, Stevenson JG, Bernstein SJ, Stiles SA, Fendrick AM (2004) Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? J Gen Intern Med 19:638-645 (Pubitemid 38803154)
12. Ess SM, Schneeweiss S, Szucs TD (2003) European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21(2):89-103 (Pubitemid 36127005)
13. Freemantle N, Bloor K (1996) Lessons from international experience in controlling pharmaceutical expenditure. I: influencing patients. Br Med J 312:1469-1471 (Pubitemid 26000750)
14. Gebregziabher M, Lynch CP, Mueller M, Gilbert GE, Echols C, Zhao Y, Egede LE (2011) Using quantile regression to investigate racial differences in medication non-adherence. BMC Med Res Methodol 11:88
15. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Shaohung W (2006) The effects of prescription drug co-payments on statin adherence. Am J Manag Care 12:509-517 (Pubitemid 44412033)
16. Hockley T, Gemmill M (2007) European cholesterol guidelines report. Policy analysis centre LSE
17. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndrome. Ann Pharmacother 39(11):1792-1797
18. Jappelli J, Pistaferri L, Weber G (2007) Healthcare quality, economic inequality, and precautionary saving. Health Econ 16(4):327-346 (Pubitemid 46566850)
19. Koenker R (2005) Quantile Regression, Cambridge University Press ISBN 0-521-60827-9
20. Luepker RV (1993) Patient adherence: A "risk factor" for cardiovascular disease. Heart Dis Stroke 2:418-421 (Pubitemid 23295613)
21. Lundberg L, Johannesson M, Isacson DGL, Borgquist L (1998) Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy 44:123-134 (Pubitemid 28275957)
22. Roy S, Madhavan SS (2008) Making a case for employing a societal perspective in the evaluation of medicaid prescription drug interventions. Pharmacoeconomics 26(4):281-296 (Pubitemid 351457476)
23. Sabate E (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva
24. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J (2005) Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 11:306-312 (Pubitemid 40646935)
25. Shrank WH, Hoang T, Ettner SL, Glassmanand PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch S (2006) The implications of choice prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 166:332-337 (Pubitemid 43244321)
26. Yoon J, Ettner S (2009) Cost-sharing and adherence to antihypertensives for low and high adherers. Am J Manag Care 15(11):833-940